Table 6.

The baseline and the outcome of two subgroups in 294 patients who were regularly followed and treated with RAS blockade alone at least 3 months

Response Patients (n = 113)Non-response Patients (n = 181)P
At time of biopsy
    age (yrs)33.8 ± 10.633.2 ± 10.90.68
    female (%)59.243.60.009
    MAP (mmHg)89.3 ± 22.981.1 ± 27.80.16
    eGFR (ml/min per 1.73 m2)89.3 ± 22.981.1 ± 27.80.009
    proteinuria (g/day)1.3 ± 0.92.8 ± 2.3<0.001
    M1 (%)55.868.50.03
    E25 (%)13.317.70.32
    S1 (%)78.882.90.38
    T0 (%)88.670.7<0.05
    T1 (%)7.916.6<0.001
    T2 (%)3.512.7<0.001
Follow-up
    duration of follow-up (months)32 (12 to 171)36 (12 to 94)0.27
    TA-Up (g/day)0.6 ± 0.21.5 ± 1.1<0.001
    TA-MAP (mmHg)85.7 ± 11.389.0 ± 12.90.03
    ESRD (%)08.80.001
    eGFR slope (ml/min per 1.73 m2 per year)0 ± 0.7−0.2 ± 0.70.06
  • eGFR, estimated GFR; MAP, mean arterial pressure; TA-MAP, time-averaged MAP; TA-Up, time-averaged proteinuria; M1, mesangial hypercellularity score >0.5; E25, endocapillary hypercellularity involving more than 25% glomeruli; C1, crescent present; S1, segmental glomerulosclerosis present; T0, tubular atrophy/interstitial fibrosis range from 0 to 25%; T1, tubular atrophy/interstitial fibrosis range from 26 to 50%; T2, tubular atrophy/interstitial fibrosis >50%.